Skip to main content

Table 2 Cox regression models for overall survival, recurrence-free-survival, and colostomy-free survival for patients living with HIV treated with definitive chemoradiation

From: The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

  Overall survival (OS) Recurrence-free Survival (RFS) Colostomy-free Survival (CFS)
Univariate Model Adjusted Model Univariate Model Adjusted Model Univariate Model Adjusted Model
HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value HR (95%CI) p-value
Age at diagnosis
  < 40 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 40–59 0.78 (0.37–1.64) 0.51 0.69 (0.29–1.60) 0.39 0.65 (0.29–1.47) 0.30 0.66 (0.28–1.54) 0.34 0.99 (0.29–3.41) 0.98 0.94 (0.26–3.34) 0.92
 60+ 1.44 (0.66–3.17) 0.36 1.65 (0.67–4.05) 0.28 0.60 (0.24–1.51) 0.28 0.53 (0.20–1.43) 0.21 0.87 (0.22–3.48) 0.85 0.79 (0.19–3.23) 0.74
Race/Ethnicity
 Caucasian 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 African American 1.25 (0.82–1.89) 0.29 1.31 (0.83–2.06) 0.25 1.32 (0.79–2.18) 0.29 1.17 (0.67–2.04) 0.57 0.98 (0.47–2.01) 0.95 1.06 (0.50–2.27) 0.87
 Hispanic 0.68 (0.29–1.60) 0.38 0.69 (0.27–1.81) 0.45 0.71 (0.25–2.02) 0.52 0.65 (0.22–1.94) 0.44 0.99 (0.29–3.35) 0.99 1.17 (0.33–4.12) 0.81
Oher/Unknown 1.64 (0.80–3.33) 0.18 2.10 (0.93–4.74) 0.07 0.98 (0.35–2.77) 0.97 1.36 (0.46–4.06) 0.58 1.39 (0.41–4.71) 0.60 1.22 (0.35–4.24) 0.75
HIV Medication
 No Protease Inhibitor 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
 Protease Inhibitor 1.04 (0.68–1.59) 0.87 0.86 (0.53–1.38) 0.53 1.53 (0.86–2.72) 0.15 1.34 (0.74–2.43) 0.33 1.07 (0.52–2.23) 0.85 1.03 (0.49–2.15) 0.94
Year HIV Diagnosed
  < 2000 1.00 Ref    1.00 Ref    1.00 Ref   
 2000–2009 0.77 (0.48–1.22) 0.26    0.82 (0.47–1.43) 0.48    1.22 (0.61–2.45) 0.58   
 2010–2016 0.98 (0.42–2.27) 0.96    0.63 (0.19–2.01) 0.43     
Smoker
 Never 1.00 Ref 1.00 Ref 1.00 Ref    1.00 Ref   
 Former 1.76 (0.96–3.22) 0.07 1.65 (0.82–3.29) 0.16 2.01 (1.01–4.00) 0.05    1.14 (0.47–2.77) 0.77   
 Current 1.45 (0.88–2.40) 0.15 1.51 (0.83–2.77) 0.18 1.12 (0.62–2.04) 0.71    0.60 (0.28–1.27) 0.18   
 Unknown 2.54 (1.16–5.55) 0.02 4.08 (1.71–9.73) < 0.01 0.97 (0.28–3.35) 0.97    0.84 (0.19–3.73) 0.82   
Stage
 I 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref   
 II 2.38 (1.17–4.82) 0.02 3.16 (1.50–6.62) < 0.01 1.75 (0.77–3.97) 0.18 1.77 (0.75–4.16) 0.19 2.06 (0.70–6.00) 0.19   
 IIIA 2.94 (1.16–7.41) 0.02 4.63 (1.67–12.82) < 0.01 1.88 (0.60–5.93) 0.28 2.03 (0.62–6.62) 0.24 2.71 (0.68–10.86) 0.16   
 IIIB 3.07 (1.44–6.53) < 0.01 3.16 (1.42–7.06) < 0.01 3.10 (1.32–7.31) < 0.01 3.01 (1.20–7.55) 0.02 1.98 (0.59–6.59) 0.27   
 IV 3.83 (1.18–12.47) 0.03 2.41 (0.69–8.42) 0.17 5.73 (1.67–19.6) < 0.01 6.14 (1.68–22.44) < 0.01   
 Unknown 3.66 (0.79–16.99) 0.10 0.94 (0.17–5.11) 0.94   
CD4 at Cancer Diagnosis
  ≤ 200 1.00 Ref    1.00 Ref    1.00 Ref   
  > 200 0.90 (0.58–1.41) 0.66    0.63 (0.38–1.06) 0.08    1.09 (0.49–2.42) 0.83   
 Unknown 1.00 (0.41–2.47) 0.99    0.59 (0.17–2.01) 0.40    1.78 (0.46–6.93) 0.40   
Nadir CD4 during Radiation
  ≤ 200 1.00 Ref    1.00 Ref    1.00 Ref   
  > 200 0.74 (0.45–1.22) 0.24    0.75 (0.42–1.33) 0.32    0.88 (0.40–1.90) 0.74   
 Unknown 2.54 (1.16–5.55) 0.76    0.64 (0.35–1.15) 0.13    0.73 (0.33–1.62) 0.43   
BMI
  < 25 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref   
 25–29.9 0.72 (0.47–1.11) 0.14 0.49 (0.30–0.81) < 0.01 0.84 (0.50–1.42) 0.51 0.62 (0.34–1.11) 0.11 1.09 (0.55–2.18) 0.81   
 ≥ 30 0.39 (0.17–0.91) 0.03 0.61 (0.25–1.51) 0.29 0.30 (0.09–0.95) 0.04 0.32 (0.10–1.06) 0.06 0.22 (0.03–1.61) 0.14   
 Unknown 1.09 (0.51–2.32) 0.82 0.76 (0.32–1.77) 0.52 0.88 (0.31–2.52) 0.82 0.71 (0.24–2.13) 0.54 1.35 (0.39–4.72) 0.63   
Alcohol Use
 No 1.00 Ref    1.00 Ref    1.00 Ref   
 Yes 0.93 (0.63–1.40) 0.74    0.69 (0.41–1.16) 0.16    0.85 (0.43–1.70) 0.65   
History of prior cancer
 No 1.00 Ref    1.00 Ref    1.00 Ref   
 Yes 0.87 (0.51–1.48) 0.60    0.71 (0.35–1.43) 0.33    0.91 (0.38–2.18) 0.83   
Radiation Modality
 2D + 3D 1.00 Ref 1.00 Ref 1.00 Ref    1.00 Ref   
 IMRT 0.65 (0.40–1.06) 0.08 0.50 (0.29–0.86) 0.01 0.70 (0.39–1.26) 0.23    0.59 (0.25–1.39) 0.22   
 Unknown 0.72 (0.46–1.13) 0.15 0.60 (0.36–0.98) 0.04 0.78 (0.45–1.37) 0.39    0.99 (0.48–2.05) 0.97   
Completed Radiation Treatment
 No 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref   
 Yes 0.40 (0.23–0.69) < 0.01 0.26 (0.14–0.50) < 0.01 0.61 (0.30–1.24) 0.17 0.44 (0.20–0.95) 0.04 1.56 (0.37–6.51) 0.54   
Length of Radiation Treatment
  ≤ 50 days 1.00 Ref    1.00 Ref 1.00 Ref 1.00 Ref 1.00 Ref
  > 50 days 1.67 (1.13–2.47) 0.01    1.48 (0.91–2.43) 0.12 1.14 (0.66–1.97) 0.63 1.55 (0.77–3.10) 0.22 1.56 (0.77–3.17) 0.22
 Unknown 2.54 (1.16–5.55) 0.15    2.87 (1.11–7.39) 0.03 3.63 (1.32–9.99) 0.01 5.34 (1.94–14.71) < 0.01 5.48 (1.93–15.55) < 0.01
Chemotherapy Regimen
 5FU + mitomycin C 1.00 Ref    1.00 Ref    1.00 Ref   
 5FU + cisplatin 1.39 (0.81–2.39) 0.23    0.84 (0.38–1.84) 0.66    1.91 (0.82–4.46) 0.13   
 Other 1.07 (0.63–1.85) 0.80    0.92 (0.47–1.81) 0.81    1.44 (0.62–3.37) 0.40   
Chemotherapy Dose Reduction
 No 1.00 Ref    1.00 Ref    1.00 Ref   
 Yes 1.40 (0.94–2.08) 0.10    1.46 (0.90–2.39) 0.13    1.23 (0.62–2.45) 0.56   
Hospitalization during treatment
 No 1.00 Ref 1.00 Ref 1.00 Ref    1.00 Ref   
 Yes 2.05 (1.40–3.00) < 0.01 1.92 (1.24–2.96) < 0.01 2.05 (1.28–3.30) < 0.01    1.37 (0.71–2.64) 0.35